Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma

• Kevin W. Song,
• Meletios A. Dimopoulos,
• Katja C. Weisel,
• Philippe Moreau,
• Antonio Palumbo,
• Andrew Belch,
• Stephen Schey,
• Pieter Sonneveld,
• Lars Sternas,
• Xin Yu,
• Ramesh Amatya,
• Mara S. Monzini,
• Mohamed Zaki,
• Christian Jacques,
• Jesus San Miguel

Affiliations

Kevin W. Song

Vancouver General Hospital, BC, Canada

Meletios A. Dimopoulos

Alexandra Hospital, Athens, Greece

Katja C. Weisel

University Hospital Tübingen, Germany

Philippe Moreau

University Hospital Hotel-Dieu, Nantes, France

Antonio Palumbo

University Hospital and Health City of Science of Torino, Italy

Andrew Belch

University of Alberta, Edmonton, Canada

Stephen Schey

King’s College Hospital and King’s College London, UK

Pieter Sonneveld

Erasmus Medical Center Rotterdam, The Netherlands

Lars Sternas

Celgene Corporation, Summit, NJ, USA

Xin Yu

Celgene Corporation, Summit, NJ, USA

Ramesh Amatya

Adelphi Values, Boston, MA, USA

Mara S. Monzini

Celgene Corporation, Summit, NJ, USA

Mohamed Zaki

Celgene Corporation, Summit, NJ, USA

Christian Jacques

Celgene Corporation, Summit, NJ, USA

Jesus San Miguel

Hospital Universitario de Salamanca, Salamanca, Spain.